Skip to main content
Trillium Therapeutics Inc. logo

Trillium Therapeutics Inc. — Investor Relations & Filings

Ticker · TRIL ISIN · CA89620X5064 TSX Professional, scientific and technical activities
Open in API
Filings indexed 397 across all filing types
Latest filing 2020-01-13 Governance Information
Country CA Canada
Listing TSX TRIL

About Trillium Therapeutics Inc.

http://www.trilliumtherapeutics.com

Trillium Therapeutics Inc. was a clinical-stage biopharmaceutical company specializing in immuno-oncology. The company focused on the discovery and development of innovative therapies for the treatment of cancer, particularly those targeting the immune system and its regulation. Trillium maintained preclinical programs and advanced several candidates through clinical trials in the oncology therapy area. In November 2021, Trillium Therapeutics was acquired by Pfizer Inc. and now operates as an integrated entity within Pfizer's global biopharmaceutical research and development structure, continuing its focus on advancing cancer treatments.

Recent filings

Filing Released Lang Actions
Other securityholders documents - English.pdf
Governance Information Classification · 95% confidence The document text consists of detailed articles of incorporation or bylaws for Trillium Therapeutics Inc., covering topics such as share structure, share certificates, shareholder meetings, voting rights, proxies, and directors. It is a legal and governance document outlining the company's internal rules and procedures. There is no indication of financial data, audit information, earnings, or management discussion. The content aligns with governance practices and internal company rules rather than financial reporting or announcements. Therefore, the document best fits the category of Governance Information (CGR). The document length is substantial and contains detailed governance provisions, supporting a high confidence in this classification.
2020-01-13 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release providing an update on clinical trial progress for Trillium Therapeutics' TTI-621 and TTI-622 programs. It includes detailed information about dose escalation, safety data, response rates, and future plans for the clinical studies. There are no financial statements, regulatory certifications, or voting results. The content focuses on clinical development updates and corporate strategy rather than financial results or governance. It is not a full annual or interim report, nor a call transcript or investor presentation. The document is a corporate update on clinical programs, which fits best under the category of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit other specific categories.
2020-01-07 English
Other securityholders documents - English.pdf
Regulatory Filings
2019-12-23 English
Other securityholders documents - English.pdf
Regulatory Filings
2019-11-14 English
News release - English.pdf
Regulatory Filings
2019-11-14 English
Interim financial statements/report – English.pdf
Regulatory Filings
2019-11-14 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.